Literature DB >> 6950958

Studies of retinoids in the prevention and treatment of cancer.

F L Meyskens.   

Abstract

Investigation of retinoids for anticancer activity in humans, either in the chemopreventive or treatment mode, has been little studied. We summarize here our ongoing investigations in four different areas: (1) secondary prevention of cervical dysplasia with topical application of all-trans-retinoic acid; (2) adjuvant treatment of resected high-risk stage I and II malignant melanoma with bacille Calmette Guérin (BCG) plus or minus oral vitamin A; (3) topical vitamin A acid therapy for cutaneous metastatic melanoma; an (4) oral isotretinoin as an anticancer agent.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6950958     DOI： 10.1016/s0190-9622(82)70072-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  4 in total

1.  Comparative study of systemic interferon alfa-2a with oral isotretinoin and oral isotretinoin alone in the treatment of recurrent condylomata accuminata.

Authors:  E K Cardamakis; I G Kotoulas; D P Dimopoulos; E N Stathopoulos; J T Michopoulos; V A Tzingounis
Journal:  Arch Gynecol Obstet       Date:  1996       Impact factor: 2.344

Review 2.  Synthetic retinoids in dermatology.

Authors:  E H Heller; N J Shiffman
Journal:  Can Med Assoc J       Date:  1985-05-15       Impact factor: 8.262

3.  Familial tylosis and carcinoma of the oesophagus.

Authors:  M Y O'Mahony; J P Ellis; M Hellier; R Mann; P Huddy
Journal:  J R Soc Med       Date:  1984-06       Impact factor: 18.000

4.  Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion.

Authors:  Satish B Cheepala; Weihong Yin; Zanobia Syed; Jennifer N Gill; Alaina McMillian; Heather E Kleiner; Mark Lynch; Rasiah Loganantharaj; Marjan Trutschl; Urska Cvek; John L Clifford
Journal:  Mol Cancer       Date:  2009-05-11       Impact factor: 27.401
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.